Post-marketing surveillance of Norplant® contraceptive implants: I. Contraceptive efficacy and reproductive health

Contraception

Volumn 63, Issue 4, 2001, Pages 167-186

  Farley, T M M ^a   Sivin, I ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLEEDING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; ECTOPIC PREGNANCY; FEMALE; FEMALE CONTRACEPTIVE DEVICE; FEMALE STERILIZATION; FOLLOW UP; HUMAN; INCIDENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; MATERNAL MORBIDITY; MULTICENTER STUDY; NORMAL HUMAN; OVARY HYPERTROPHY; PELVIC INFLAMMATORY DISEASE; POSTMARKETING SURVEILLANCE; PREGNANCY RATE; REPRODUCTIVE HEALTH; SAFETY; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINITIS;

ABDOMINAL PAIN; ADULT; BREAST NEOPLASMS; CONTRACEPTIVE AGENTS, FEMALE; DEVELOPING COUNTRIES; DRUG IMPLANTS; FEMALE; FERTILITY; HUMANS; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; MARITAL STATUS; OVARIAN CYSTS; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PREGNANCY, ECTOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; STERILIZATION, TUBAL; UTERINE CERVICAL NEOPLASMS; UTERINE HEMORRHAGE; UTERINE NEOPLASMS; VAGINAL DISCHARGE; VAGINITIS;

EID: 0035306070     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00188-3     Document Type: Article

References (43)

1. World Health Organization. Facts about an implantable contraceptive memorandum from a WHO Meeting. Bull World Health Org. 63:1985;485-494.
2. R -2 contraceptives. Stud Fam Plann. 19:1988;81-94.
3. R implants. Human Reprod. 9:1994;1818-1826.
4. Fraser I.S., Tiitinen A., Affandi B., et al. Norplant consensus statement and background review. Contraception. 57:1998;1-9.
5. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Guidelines for the toxicological and clinical assessment and post-registration surveillance of steroidal contraceptive drugs. 1987;World Health Organization, Geneva.
6. International Collaborative Post-Marketing Surveillance of Norplant. Post-marketing surveillance of Norplant contraceptive implants II Non-reproductive health. Contraception. 63:2001;187-209.
7. R implants. Contraception. 35:1987;551-567.
8. Lamberts H., Wood M. International classification of primary care. 1987;Oxford University Press, Oxford.
9. World Health Organization. International statistical classification of diseases, injuries, and causes of death, 9th revision. 1977;World Health Organization, Geneva.
10. World Health Organization. International classification of procedures in medicine, Volume 1 and 2. 1978;World Health Organization, Geneva.
11. Farley T.M.M. Life-table methods for contraceptive research. Stat Med. 5:1986;475-489.
12. Chiang C.L. A stochastic study of the life table, and its applications III. The follow-up study with the consideration of competing risks. Biometrics. 17:1961;57-78.
13. Tietze C. Intra-uterine contraception recommended procedures for data analysis. Stud Fam Plann. 18:(Suppl):1967;1-6.
14. Gardner M.J., Altman D.G. Statistics with confidenceconfidence intervals and statistical guidelines. 1989;BMJ, London.
15. StataCorp. Stata Statistical Software Release 5.0. College Station. 1997;Stata Corporation, TX.
16. World Health Organization Task Force on Safety and Efficacy of Fertility Regulation Methods. The TCu380A, Tcu220C, Multiload 250 and Nova T IUDs at 3, 5 and 7 years of useresults from three randomized clinical trials. Contraception. 42:1990;141-158.
17. Sivin I., Stern J., Coutinho E., et al. Prolonged intrauterine contraception a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDs. Contraception. 44:1991;473-480.
18. Sivin I., Schmidt F. Effectiveness of IUDs. Contraception. 36:1987;55-84.
19. Peterson H., Xia Z., Wilcox L.S., Ratcliff Tyler L., Trussel J. for the U.S. Collaborative Review of Sterilization Working Group. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-70.
20. Hatcher R.A., Trussel J., Stewart G.K., et al., editors. Contraceptive Technology. New York: Irvington Publisher, Inc., 1994.
21. World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices. Technical Report Series 753. 1987;World Health Organization, Geneva.
22. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol. 78:1991;291-298.
23. Vessey M.P., Yeates D., Flavel R. Risk of ectopic pregnancy and duration of use of an intrauterine device. Lancet. ii:1979;501-502.
24. Sivin I., Stern J., Díaz S., et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods or levonorgestrel-releasing or Copper TCu 380 Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 166:1992;1208-1213.
25. Poston D.L. Jr, Gu B., Liu P.P., McDanial T. Son preference and the sex ratio at birth in China a Provincial level analysis. Soc Biol. 44:1997;55-76.
26. International Agency for Research on Cancer. Cancer incidence in Five Continents. Vol VI. 1992;IARC Scientific Publications No. 120, Lyon, France.
27. Armstrong B.K., Munoz N., Bosch F.X. Epidemiology of cancer of the cervix. Coppleson M., Monaghan J.M., Morrow C.P., Tattersall M.H.N., Gynecologic oncology. 1999;11-29 Churchill Livingstone, Edinburgh.
28. Ross R.K., Pike M.C., Vessey M., Bull D., Yeates D., Casagrande J.T. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. Br Med J 1986:359-62.
29. Lumbiganon P., Rugpao S., Phandhu-fung S., Laopaiboon M., Vudhikamrksa N., Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas a multicentre case-control study. Br J Obstet Gynaecol. 103:1995;909-914.
30. Peralta O., Pavez M., Diaz S., Croxatto H.B. Patologia anexial no inflamatoria durante el uso de implantifs de levonorgestrel (Norplant) o dispositivos intrauterinos. Rev Chil Obstet Ginecol. 55:1990;231-237.
31. Shoupe D., Lacarra M., Horenstein J., Medearis A., Mishell D.R. Jr. Characteristics of ovarian follicular development in Norplant users. Fertil Steril. 55:1991;766-770.
32. Farley T.M.M., Rosenberg M.J., Rowe P.J., Chen J.H., Meirik O. Intrauterine devices and pelvic inflammatory disease an international perspective. Lancet. 139:1992;785-788.
33. Lee N.C., Rubin G.L., Borucki R. The intrauterine device and pelvic inflammatory disease revisited new results from the Womens's Health Study. Obstet Gynecol. 72:1988;1-6.
34. Buchan H., Villard-Mackintosh L., Vessey M., Yeates D., McPherson K. Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br J Obstet Gynaecol. 97:1990;780-788.
35. R subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception. 36:1987;193-201.
36. Wolner-Hansen P. Relationship between oral contraceptives and pelvic inflammatory disease and associated sexually transmitted diseases. Hannaford P.C., Webb A.M.C., Evidence-guided prescribing of the pill. 1996;175-180 The Parthenon Publishing Group, New York.
37. Faundes A., Tejada, Brache V., Alvarez F. Subjective perception of bleeding and serum ferritin concentration in long-term users of Norplant. Contraception. 35:1987;189-196.
38. Diaz S., Pavez M., Herreros C., Johansson E.D., Croxatto H.B. Recovery of fertility and outcome of accidental pregnancies after the removal of Norplant® subdermal implants or Copper-T IUDs. Contraception. 35:1987;569-579.
39. Affandi B., Santos S.S., Djajadilaga, et al. Pregnancy after removal of Norplant® implant contraceptives. Contraception. 36:1987;203-209.
40. Affandi B. Pregnancy after removal of etonorgestrel implant contraceptive (Implanon®). Med J Indones. 8:1999;62-64.
41. Vessey M., Doll R., Peto R., Johnson B., Wiggins P. A long-term follow-up study of women using different methods of contraceptionan interim report. J Biosoc Sci. 8:1976;373-427.
42. Royal College of General Practitioners. Oral Contraceptives and Health. 1974;Pitman Medical, London.
43. Ramcharan S., Pellegrin F.A., Ray R.M., Hsu J.P. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Vol III, an interim report a comparison of disease occurrence leading to hospitalization or death in users and non-users of oral contraceptives. J Reprod Med. 25:(Suppl 6):1980;345-372.